

**GENEVIEVE P. KANTER**

**Business address:**

Sol Price School of Public Policy  
Schaeffer Institute for Public Policy  
& Government Service  
University of Southern California  
635 Downey Way, VPD 512-J  
Los Angeles, CA 90089

**Contact:**

Tel: 215.375.2925  
gpkanter@kanter-research.org  
<https://kanter-research.org>

**Education**

- 2001-09     PhD Economics & PhD Sociology  
University of Chicago, Chicago, IL  
Department of Economics and Department of Sociology  
*Fields:* Labor-Human Capital & Econometrics-Statistics (Economics)  
Social Stratification & Methodology (Sociology)  
High Pass, PhD Preliminary Exam in Sociology
- 1996-97     MPhil Economics  
University of Cambridge, Trinity College, Cambridge, UK  
Faculty of Economics and Politics
- 1995-96     Diploma Economics  
University of Cambridge, Trinity College, Cambridge, UK  
Faculty of Economics and Politics
- 1989-91     MS Tropical Public Health  
Harvard University, Cambridge, MA  
Harvard TH Chan School of Public Health  
Matriculated and completed 2 years as doctoral student in Division of Biological Sciences
- 1986-89     BSE Biomedical Engineering, election to *Tau Beta Pi* and *Alpha Eta Mu Beta*  
University of Iowa, Iowa City, IA  
College of Engineering
- 1985-86     Completed first year of engineering studies  
University of Michigan, Ann Arbor, MI  
College of Engineering

**Current Appointments**

2023- Associate Professor (tenured)  
University of Southern California Sol Price School of Public Policy, Los Angeles, CA  
Department of Health Policy and Management

*Affiliations*

2022- Senior Scholar, USC Schaeffer Institute for Public Policy and Government Service  
2026- External Affiliate, UCLA California Center for Population Research

**Previous Appointments**

2017-22 Research Assistant Professor (research-track)  
University of Pennsylvania Perelman School of Medicine, Philadelphia, PA  
Department of Medicine, Division of General Internal Medicine  
Department of Medical Ethics & Health Policy, Division of Medical Ethics (secondary)  
  
Director, Wharton Public Policy Certificate Program (2021-22)  
University of Pennsylvania Wharton School, Philadelphia, PA  
Penn Wharton Budget Model

2014-17 Assistant Professor (tenure-track)  
Drexel University Dornsife School of Public Health, Philadelphia, PA  
Department of Health Management & Policy

2011-14 Assistant Professor (tenure-track)  
(On Leave University of Colorado, Denver, CO  
2011-13) Colorado School of Public Health, Department of Health Systems, Management & Policy  
Department of Economics (secondary)

2011-15 Edmond J. Safra Lab Fellow (Residential 2011-2013, Non-Residential 2013-2015)  
Harvard University, Cambridge, MA  
Edmond J. Safra Center for Ethics

2011-13 Research Fellow  
Massachusetts General Hospital, Boston, MA  
Mongan Institute for Health Policy

2009-11 NIH (NICHD) Postdoctoral Research Fellow  
Princeton University, Princeton, NJ  
Woodrow Wilson School of Public and International Affairs  
Office of Population Research and Center for Health and Wellbeing

- 1998-2001 Associate Economist  
Federal Reserve Bank of Chicago, Chicago, IL  
Research Department, Macroeconomics Team
- 1993-95 Research Scientist  
Medical Research Council of South Africa, Johannesburg, South Africa  
National HIV/AIDS Research Programme
- 1992, 1993 Short-Term Consultant, Intern  
World Bank, Washington, DC  
Africa Region, South Central and Indian Ocean (AF3) and Technical (AF5)

**Selected Honors and Awards**

- 2024, 2025 Bronze Level Research Award, University of Southern California
- 2024- Full Member, Sigma Xi (Scientific Research Honor Society)
- 2017 Finalist, Mentor Recognition Award  
Drexel University Dornsife School of Public Health
- 2016 Finalist, Golden Apple Teaching Excellence Award  
Drexel University Dornsife School of Public Health
- 2014 Chancellor's Teaching Award  
University of Colorado Anschutz Medical Campus and University of Colorado Denver
- 2008 Outstanding Graduate Student Paper Award  
American Sociological Association Aging & Life Course Section
- 2007-09 NIH (NIA) Predoctoral Fellowship  
University of Chicago Center on Aging
- 2007-09 Graduate Scholar  
University of Chicago Becker Friedman Institute for Research in Economics
- 2006-07 NIH (NIMH) Predoctoral Fellowship  
American Sociological Association MFP
- 2005-06 Predoctoral Fellowship  
Chicago Center of Excellence in Health Promotion Economics
- 2002 High Pass (highest honors), Department of Sociology Preliminary Exams  
University of Chicago

|         |                                                                                                                                  |
|---------|----------------------------------------------------------------------------------------------------------------------------------|
| 2001-05 | Century Fellowship, highest distinction university fellowship<br>University of Chicago                                           |
| 1988    | Election to Alpha Eta Mu Beta, national biomedical engineering honor society<br>Founding Chapter Member and Secretary, 1988-1989 |
| 1987    | Election to Tau Beta Pi, national engineering honor society<br>Vice President, 1988-1989                                         |
| 1985    | National Merit Scholarship                                                                                                       |

### **Peer-Reviewed Publications**

#### Sole-Authored Peer-Reviewed Publications

1. **Kanter GP.** Prediction markets in clinical trials and drug approval. JAMA Health Forum 2026; 7:e262953. [\[Link\]](#) [peer-reviewed commentary]
2. **Kanter GP.** Conflicts of interest in advisory committees – facts, fallacies, and the limits of reform. N Engl J Med 2026; 394:1150-1152. [\[Link\]](#) [\[PDF\]](#) [peer-reviewed commentary]
3. **Pham-Kanter G.** Revisiting conflicts of interest in FDA advisory committees. Milbank Q 2014; 92:446-447. [\[Link\]](#) [\[PDF\]](#)
4. **Pham-Kanter G.** Social comparisons and health: can having richer friends and neighbors make you sick? Soc Sci Med 2009; 69:335-344. [\[Link\]](#) [\[PDF\]](#)  
American Sociological Association Aging & Life Course Section  
2008 Outstanding Graduate Student Paper Award

#### First-Authored or Senior-Authored Peer-Reviewed Publications

\*student or advisee

5. **Kanter GP, \*Mankowitz T.** Prevalence of ties to industry-funded organizations among patient and consumer representatives on FDA advisory committees. Health Affairs Schol 2026; qxag296. [\[Link\]](#)
6. **Kanter GP, \*Mankowitz T, Lurie P.** Conflicts of interest in federal vaccine advisory committees. JAMA 2025; 334:1295-1297. [\[Link\]](#) [\[PDF\]](#)
7. Holmgren AJ, Apathy N, **Kanter GP.** Electronic health record market consolidation and implications for cybersecurity. Health Affairs Scholar 2025; 3(8); qxaf164. [\[Link\]](#) [peer-reviewed commentary]
8. \*Rekowski J, \*Kannarkat J, Packel EA, **Kanter GP.** Cyber attacks and the dark web – primer for physicians. Missouri Medicine. September/October 2025. [\[Link\]](#)

9. Weissman GE, \*Mankowitz T, **Kanter GP**. Unregulated large language models produce medical device-like output. npj Digital Medicine 2025; 8:148. [\[Link\]](#)
10. **Kanter GP**, \*Rekowski J, \*Kannarkat J. Lessons from the Change Healthcare ransomware attack. JAMA Health Forum 2024; 5:e242764. [\[Link\]](#) [peer-reviewed commentary]
11. **Kanter GP**, Ozluk P, Chi W, Fisch MJ, Debono D, Parikh RB, Jacobson M, Bekelman JE, DeVries A. Cancer treatment before and after physician-pharmacy integration. JAMA Netw Open 2024; 7:e2412998. [\[Link\]](#)
12. **Kanter GP**, Carpenter D. The revolving door in health care regulation. Health Aff 2023; 42:1298-1303. [\[Link\]](#)
13. **Kanter GP**, Packel EA. Health care privacy risks of AI chatbots. JAMA 2023; 330:311-312. [peer-reviewed commentary]
14. **Kanter GP**, Parikh RB, Fisch MJ, Debono D, Bekelman J, Xu Y, Schauder S, Sylwestrzak G, Barron JJ, Cobb R, Qato DM, Jacobson M. Trends in medically integrated dispensing among oncology practices. JCO Oncol Pract 2022; e1672-e1682.
15. Lin E, McCoy M, Berns J, **Kanter GP**. Association between nephrologist ownership of dialysis facilities and outcomes. JAMA Intern Med 2022; 182:1267-1276.
16. Ko EM, Bekelman JE, \*Hicks-Courant K, Brensinger CM, **Kanter GP**. Association of gynecologic versus medical oncology specialty with survival, utilization, and spending for treatment of gynecologic cancers. Gynecol Oncol 2022; 164: 295-303.
17. **Kanter GP**, Kufahl J, Cohen IG. Beyond security patches—fundamental incentive problems in health care cybersecurity. JAMA Health Forum 2021; 2:e212969. [peer-reviewed commentary]
18. McCoy MS, Joffe S, \*Bonci M, **Kanter GP**. Historical trends in health-care related financial holdings among members of Congress. PLoS ONE 2021; e0253624.
19. **Kanter GP**, Segal AN, Groeneveld PW. Income disparities in access to critical care services. Health Aff 2020; 39:1362-1367.
20. **Kanter GP**, \*Nabet B, Matone M, Rubin DM. Association of state Medicaid expansion with hospital community benefit spending. JAMA Netw Open 2020; 3:e205529.
21. Groeneveld PW, Yang L, Segal A, Karaca-Mandic P, **Kanter GP**. The effects of market competition on cardiologists' adoption of transcatheter aortic valve replacement. Med Care 2020; 58:996-1003.
22. **Kanter GP**, Loewenstein G. Evaluating Open Payments. JAMA 2019; 322:401-402. [peer-reviewed commentary]

23. **Kanter GP**, Pauly MV. Coordination of care or conflict of interest? Exempting ACOs from the Stark law. N Engl J Med 2019; 381:410-411. [peer-reviewed commentary]
24. **Kanter GP**, Polsky D, Werner RM. Changes in physician consolidation with the spread of Accountable Care Organizations. Health Aff 2019; 38:1936-1943.
25. **Kanter GP**, Carpenter D, Lehmann LS, Mello MM. US nationwide disclosure of industry payments and public trust in physicians. JAMA Netw Open 2019; 2:e191947.
26. **Kanter GP**, Carpenter D, Lehmann LS, Mello MM. Effect of the public disclosure of industry payments information on patients: Results from a population-based natural experiment. BMJ Open 2019; 9:3024020.
27. Grimberg A, **Kanter GP**. US growth hormone use in the idiopathic short stature era: Trends in insurer payments and patient financial burden. J Endocr Soc 2019; 3:2023-2031.
28. McCoy MS, **Kanter GP**. Campaign contributions from political action committees to members of Congressional committees responding to the opioid crisis. JAMA 2018; 320:1489-1491.
29. Zhong Y, Auchincloss AH, Lee B, **Kanter GP**. The short-term impacts of the Philadelphia beverage tax on beverage consumption. Am J Prev Med 2018; 55:26-34.
30. **Pham-Kanter G**, Mello MM, Lehmann LS, Campbell EG, Carpenter D. Public awareness of and contact with physicians who receive industry payments: a national survey. J Gen Intern Med 2017; 32:767-774.
31. \*Kern DM, Auchincloss AH, Robinson LF, Stehr MF, **Pham-Kanter G**. Healthy and unhealthy food prices across neighborhoods and their association with neighborhood socioeconomic status and proportion black/Hispanic. J Urban Health 2017; 94: 494-505.
32. **Pham-Kanter G**, Zinner DE, Campbell EG. Codifying collegiality: developments in data sharing policy in the life sciences. PLoS ONE 2014; 9:e108451.
33. \*Gorlach I, **Pham-Kanter G**. Brightening up: The effect of the physician payment sunshine provision on existing regulation of pharmaceutical marketing. J Law Med Ethics 2013; 41:315-322.
34. Campbell EG, **Pham-Kanter G**, Vogeli C, Iezzoni LI. Physician acquiescence to patient demands for brand name drugs. JAMA Intern Med 2013; 173:237-239.
35. Wakeman S, Baggett MV, **Pham-Kanter G**, Campbell EG. Internal medicine residents' training in substance use disorders: a survey of the quality of instruction and resident self-perceived preparedness to diagnose and treat addiction. Subst Abus 2013; 34:363-370.
36. **Pham-Kanter G**, Alexander GC, Nair K. Effect of physician payment disclosure laws on prescribing. Arch Intern Med 2012; 172:819-821.

37. **Pham-Kanter G**, Goldman N. Can sons reduce parental mortality? *J Epidemiol Community Health* 2012; 66:710-715.
38. **Pham-Kanter G**, Steinberg MH, Ballard RC. Sexually transmitted diseases in South Africa. *Genitourin Medicine* 1996; 72:160-71.

Co-Authored (Non-First- or Non-Senior-Authored) Peer-Reviewed Publications

\*student or advisee

39. Keetley HM, Zakaria Z, Gallagher G, **Kanter GP**, Mitchell AP. How often do oncologists receive industry payments from competing companies? *The Oncologist* 2026. [[Link](#)]
40. Murayama A, Tarras ES, Freeman LM, **Kanter GP**, Marshall DC. Industry payments and prescribing patterns of antifibrotic therapy for idiopathic pulmonary fibrosis in the United States. *Respir Med* 2026; April-May: 108774. [[Link](#)]
41. Wu J, **Kanter GP**, Wagner TH, Chu D, Cashy JP, Prigge JM, Glorioso TJ, Rahman N, Murali N, Giri J, Nathan AS, Waldo SW, Groeneveld PW. Impact of the MISSION Act on quality and outcomes of major cardiovascular procedures among veterans. *JAMA* 2025; 334:702-713. [[Link](#)]  
2026 Top 10 Finalist, Clinical Research Forum Clinical Research Achievement Award
42. Nguyen D, Murayama A, Li T, Cheruvathur JS, Freeman LM, Wallis CJD, Rosella LC, Kulkarni GS, **Kanter GP**, Marshall DC, Ross JS, Detsky AS. Payments to health care professionals and teaching hospitals by AI-and machine learning-enabled medical device manufacturers. *JAMA* 2025; 334:1669-1672.
43. [alphabetical order except for first- and last-author] McCoy MS, Gaines M, Joffe S, **Kanter GP**, Largent E, Lo B, Lynch HF, Whelan AM, Mello MM. A framework for assessing the permissibility of academic leaders' outside activities. *Milbank Quarterly* 2025; 103:0610. <https://doi.org/10.1111/1468-0009.70024>
44. Guadamuz J, Alexander GC, **Kanter GP**, Qato DM. Medicare Part D preferred pharmacy networks and risk of pharmacy closure, 2014-2021. *Health Affairs* 2025; 44:539-545.
45. Kakani P, Navangul S, Luo CL, Tormohlen KN, **Kanter GP**, Landrum MB, Keating NL, Bond AM. The use of and steering to insurer-PBM owned pharmacies in Medicare. *JAMA Health Forum* 2025; 6:e244874.
46. Guadamuz J, Alexander GC, **Kanter GP**, Qato DM. More US pharmacies closed than opened in 2018–21; Independent pharmacies, those in Black, Latinx communities most at risk. *Health Aff* 2024; 43:1703-1711.
47. Lau-Min KS, Wu Y, Rochester S, Bekelman JE, **Kanter GP**, Getz KD. Association between targeted cancer drug net health benefit and uptake, patient out of pocket spending, and total spending. *J Natl Cancer Inst* 2024; 116:1479-1486.

48. Potluri VS, Reddy YNV, Tummalapalli SL, Peng C, Huang Q, **Kanter GP**, Zhu J, Liao JM, Navathe A. Early effects of the End-Stage Renal Disease Treatment Choices model on kidney transplant waitlist additions by race and ethnicity. Clin J Am Soc Nephrol 2024. 10.2215.
49. Liao JM, Kilaru AS, Wang E, Zhao Y, Zhu J, Ng G, Shirk T, Cousins D, **Kanter GP**, Ibrahim S, Navathe A. Association between mandatory bundled payments and changes in socioeconomic disparities for joint replacement outcomes. Health Serv Res 2024; 59: e14369.
50. Adusumalli S, **Kanter GP**, Small DS, Asch DA, Volpp KG, Park S, Gilteman Y, Do D, Leri D, Rhodes C, VanZandbergen C, Howell JT, Epps M, Cavella AM, Wenger M, Harrington TO, Clark K, Westover JE, Snider CK, Patel MS. Effect of nudges to clinicians, patients, or both to increase statin prescribing: A cluster randomized trial. JAMA Cardiol 2023; 8:23-30.
51. Lee JT, Moffett AT, Maliha G, Faraji Z, **Kanter GP**, Weissman GE. Analysis of a public database of predictive devices authorized by the FDA for bedside clinical decision support in critical care. JAMA Intern Med 2023; 183:1399-1401.
52. Patel MS, Volpp KG, Small DS, **Kanter GP**, Park SH, Evans CN, Polsky D. Using remotely monitored patient activity patterns after hospital discharge to predict 30 day hospital readmission: A randomized trial. Sci Rep 2023; 13:8258.
53. Smith AJB, Mulugeta-Gordon, Pena D, **Kanter GP**, Bekelman JE, Haggerty A, Ko EM. Insurance and racial disparities in prior authorization in gynecologic oncology. Gyn Onc Reports 2023; 46:1011159.
54. \*Hicks-Courant K, **Kanter GP**, Schapira M, Brensinger CM, Liu Q, Ko EM. Intensity of end-of-life care for gynecologic cancer patients by primary oncologist specialty. Int J Gynecol Cancer 2022; 32:695-703.
55. Hoffecker G, **Kanter GP**, Xu Y, Matthai W, Kolanky DM, Giri J, Tuteja S. Interventional cardiologists' attitudes towards pharmacogenetic testing and impact on antiplatelet prescribing decisions. Per Med 2022; 19:41-49.
56. Smith AJB, Mulugeta-Gordon L, Pena D, **Kanter GP**, Bekelman JE, Haggerty AE, Ko EM. Prior authorization in gynecologic oncology: An analysis of clinical impact. Gynecol Oncol 2022; 167:519-522.
57. Guadamuz JS, Alexander GC, Zenk SN, **Kanter GP**, Wilder JR, Qato DM. Access to pharmacies and pharmacy services in New York City, Los Angeles, Chicago, and Houston, 2015-2010. J Am Pharm Assoc 2021; 61:e32-e41.
58. \*Hicks-Courant K, **Kanter GP**, Giuntoli RL, Schapira MM, Bekelman JF, Latif NA, Haggerty AF, Morgan MA, Burger R, Ko EM. An increase in multi-site practices: the shifting paradigm for gynecologic cancer care delivery. Gynecol Oncol 2020; 159:283-284.
59. Strane D, **Kanter GP**, Matone M, Glaser, Rubin DM. Growth of public coverage among working families in the private sector. Health Aff 2019; 38:1132-1139.

60. Werner RM, **Kanter GP**, Polsky D. Association of physician group participation in accountable care organizations with patient social and clinical characteristics. *JAMA Netw Open* 2019; 2:e187220.
61. Rubin DM, Kenyon CC, Strane D, Brooks E, **Kanter GP**, Luan X, Bryant-Stephens T, Rodriguez R, Gregory EF, Wilson L, Hogan A, Stack N, Ward K, Dougherty J, Biblow R, Biggs L, Keren R. Association of a targeted population health management intervention with hospital admissions and bed-days for Medicaid-enrolled children. *JAMA Netw Open* 2019; 2:e1918306.
62. McCoy MS, Pagan O, Donohoe G, **Kanter GP**, Litman RS. Conflicts of interest of public speakers at meetings of the Anesthetic and Analgesic Drug Products Advisory Committee. *JAMA Intern Med* 2018; 178:996-997.
63. \*Kern DM, Auchincloss AH, Stehr MF, Diez-Roux AV, Moore KA, **Kanter GP**, Robinson LF. Neighborhood price of healthier food relative to unhealthy food and its association with type 2 diabetes and insulin resistance: The multi-ethnic study of atherosclerosis. *Prev Med* 2018; 106: 122-129.
64. Wakeman S, **Pham-Kanter G**, Donelan K. Institutional substance use disorder intervention improves general internist preparedness, attitudes, and clinical practice. *J Addict Med* 2017; 37:635-641.
65. \*Kern DM, Auchincloss AH, Stehr MF, Diez-Roux AV, Moore LV, **Kanter GP**, Robinson LF. Neighborhood prices of healthier and unhealthier foods and associations with diet quality: evidence from the Multi-Ethnic Study of Atherosclerosis. *Int J Environ Res Public Health* 2017; 14:1394.
66. Wakeman S, **Pham-Kanter G**, Donelan K. Attitudes, practices, and preparedness to care for patients with substance use disorder: results from a survey of general internists. *Subst Abus* 2016; 37:635-641.
67. Zinner DE, **Pham-Kanter G**, Campbell EG. The changing nature of scientific sharing and withholding in academic life sciences research: trends from national surveys in 2000 and 2013. *Acad Med* 2016; 91:433-440.
68. Arias JJ, **Pham-Kanter G**, Gonzalez R, Campbell EG. Trust, vulnerable populations, and data sharing. *J Law Biosci* 2015; 2:747-753.
69. Wakeman S, **Pham-Kanter G**, Baggett MV, Campbell EG. Medicine resident preparedness to diagnose and treat substance use disorders: impact of an enhanced addiction curriculum. *Subst Abus* 2015; 36:427-33.
70. Arias JJ, **Pham-Kanter G**, Campbell EG. The growth and gaps of genetic data sharing policies in the United States. *J Law Biosci* 2015; 2:56-68.
71. Williams SR, **Pham-Kanter G**, Leitsch S. Measures of chronic diseases associated with aging in the National Social Life, Health, and Aging Project. *J Gerontol B Psychol Sci Soc Sci* 2009; 64(S1):i67-i75.

**Working Papers**

1. **Kanter GP.** Managing conflicts of interest and industry in federal advisory committees. Working Paper.
2. Duquette NJ, **Kanter GP**, Karol S. "B" is for "Big Gifts": Characterizing donor-recipient charitable relationships using Form 990 Schedule B. SSRN Working Paper. Forthcoming in National Tax Journal. [\[Link\]](#)
3. Kakani P, Yde E, **Kanter GP**, Frank R, Bond A. Profit regulation and strategic transfer pricing by vertically integrated firms: evidence from health care. NBER Working Paper 35043. April 2026. Under review. [\[Link\]](#)

**Invited and Other Commentary in Peer-Reviewed Publications**

1. **Kanter GP.** The real question FDA is asking its advisory committees. JAMA Health Forum 2023; 4:e231234.
2. **Kanter GP.** COVID-19 and the future of drug marketing. JAMA Health Forum 2020; 1:e201081.
3. **Kanter GP.** Public comments and industry interests in Medicaid coverage decisions. JAMA Intern Med 2020; 180:331-332.
4. **Kanter GP.** Extending the Sunshine Act from physicians to patient advocacy organizations. Am J Public Health 2018; 108:978-979.
5. **Pham-Kanter G.** Act II of the Sunshine Act. PLoS Med 2014; 11:e1001754.

**Reports and Other Publications**

1. *Contribution in:* Community Epidemiology and Program Evaluation Group. CEPEG independent evaluation of patient navigator and community health worker components. Report for the Colorado Department of Public Health. March 2014.
2. [alphabetical order] Evans, CL, Liu CT, **Pham-Kanter G.** The 2001 recession and the Chicago Fed National Activity Index: Identifying business cycle turning points. *Economic Perspectives* 2002; 26:25-43.
3. *Contribution in:* World Bank. Better Health in Africa. Report No 12577-AFR. Washington, DC: World Bank; December 1993.

**Contributions in Edited Volumes**

1. **Pham-Kanter G.** Conflicts of interest in FDA advisory committees: the paradox of multiple financial ties. In: Lynch HF, Cohen IG, eds. *FDA in the 21<sup>st</sup> Century: The Challenges of Regulation of Drugs and New Technologies*. New York: Columbia University Press; 2015. [\[Link\]](#) [\[PDF\]](#)
2. **Pham-Kanter G.** AIDS. In: Gale Encyclopedia of Nursing and Allied Health. Detroit, MI: Gale Group; 2004.
3. **Pham-Kanter G.** Biomedical engineering. In: Gale Encyclopedia of Nursing and Allied Health. Detroit, MI: Gale Group; 2004.
4. **Pham-Kanter G.** Electrotherapy. In: Gale Encyclopedia of Nursing and Allied Health. Detroit, MI: Gale Group; 2004.
5. **Pham-Kanter G.** Medical physics. In: Gale Encyclopedia of Nursing and Allied Health. Detroit, MI: Gale Group; 2004.
6. **Pham-Kanter G.** Positron emission tomography (PET) unit. In: Gale Encyclopedia of Nursing and Allied Health. Detroit, MI: Gale Group; 2004.
7. **Pham-Kanter G.** Sports injuries. In: Gale Encyclopedia of Nursing and Allied Health. Detroit, MI: Gale Group; 2004.
8. **Pham-Kanter G.** Substance abuse and dependence. In: Gale Encyclopedia of Medicine, Second Edition. Detroit, MI: Gale Group; 2004.  
Also published in: Gale Encyclopedia of Children's Health: Infancy Through Adolescence. Detroit, MI: Gale Group; 2006.

**Op-Ed and Popular Commentary**

1. **Kanter GP.** I study conflicts of interest. Here's why RFK Jr's approach to the vaccine advisory committee could backfire. STAT. June 12, 2025.
2. **Kanter GP.** Self-regulation doesn't work – even for Supreme Court justices. The Hill. December 5, 2023.
3. Gupta R, Schwartz JL, Ross JS, **Kanter GP.** During COVID-19, FDA's vaccine advisory committee has worked to boost public trust — it can still do more. Health Affairs Blog. February 26, 2021.
4. **Kanter GP.** Science journal editors shouldn't contribute to politicizing science. STAT. October 23, 2020.
5. **Kanter GP.** More signal, less noise about industry payments to doctors. STAT. May 7, 2019.

6. McCoy MS, **Kanter GP**. The real Chris Collins scandal: lax conflict-of-interest rules in Congress. STAT. August 14, 2018.
7. **Pham-Kanter G**. Is Obama's FDA nominee too close to industry? Philly.com. November 19, 2015.

**Teaching** (UG: undergraduate; G: graduate)

**University of Southern California**

PPD 499 Health Policy and Law (UG): 2026-27

PPD 325 Fundamentals of Health Policy and Management (UG): 2022-23; 2023-24; 2024-25; 2025-26; 2026-27

PPD 202 Health and Health Care in America Today (joint with Dana Goldman) (UG): 2024-25

PPD 514 Economic Concepts Applied to Health (G): 2022-23; 2025-26

**University of Pennsylvania**

HCMG 250/850 The American Health Care System: Policy, Politics, and Reform (joint with Ezekiel Emanuel and Amol Navathe) (UG/G): 2019-20; 2020-21; 2021-22

HCMG 101 Health Care Systems (UG): 2017-18

**Drexel University**

PBHL 508 Health Care Data Analytics (G): 2015-16, 2016-17

PBHL 852 Health Economics I (G): 2014-15, 2015-16, 2016-17

PBHL 853 Health Economics II (G): 2014-15, 2015-16, 2016-17

**University of Colorado**

HSMP 7607 Methods in Health Services Research I (G-PhD): 2013-14

PBHL 3030 Health Policy (joint with Sharon Devine) (UG): 2013-14

PUBH 9655 MPH Capstone (joint with multiple faculty) (G): 2012-13

**University of Chicago**

ECON 28700 The Economics of Crime (Teaching Assistant for Steven Levitt) (UG): 2005-06; 2006-07

**Guest Lecturer**

Pharmaceutical Markets and the FDA

PPD 415 Health Policy, USC (2024)

3 Ps of Intellectual Convergence

PPD 710b Research Seminar, USC (2023, 2024)

Case Study: Propensity Score Methods

HPR 607 Research Methods II: Causal Inference, Penn (2018, 2019, 2021)

Income Disparities in Access to Critical Care Services

BIOE 5780 Bioethics, Health, and Human Rights, Penn (2020)

Conflicts of Interest in Biomedical Research

Fellowship in Advanced Biomedical Ethics Proseminar, Penn (2020)  
Antitrust Issues in Health Care  
Master of Health Care Innovation program, Penn (2020)  
Economic Issues in Precision Medicine  
Wharton Aresty Institute of Executive Education, Penn (2019)  
Risk-Benefit Analysis in Regulatory Decision-Making  
FDA-Penn Certificate Program in Pharmacoepidemiology, US FDA (2019)  
The Economics of Prescription Drug Pricing and Financing  
Robert Wood Johnson Clinical Scholars Program, Penn (2016)  
The Economics and Regulation of Health Care Markets  
Health Law II, Drexel (2016)  
Conflicts of Interest  
MA 750.0 Medical Ethics and Professionalism, Harvard (2012)

### **Advising**

\*advisee was co-author on research manuscript

### **Post-Doctoral Advising**

Felipe Montano-Campos, PhD, USC (2025-)  
Dennis Lee, PhD, USC (2025-)  
Jose Scott, PhD, USC (2025-)

### **Doctoral Dissertation Committees**

Ruixi Xu, PhD Health Economics, USC (2026-)  
Yugen Chen, PhD Economics, USC (2025-)  
David Kern\*, PhD Epidemiology, Drexel (2015-16)

### **Graduate and Clinical Research Advising**

Ravi Gupta\*, National Clinical Scholars Program, Penn (2020-22)  
John Lin, MS Health Policy Research, Penn (2020-22)  
Katherine Hicks-Courant\*, MS Health Policy Research, Penn (2019-21)

### **Master's Project Advising**

Cinthya Alberto, MPH, Drexel (2016-17)

- Winner of Departmental Award for Best Master's Project

Bardia Nabet\*, MPH, Penn (2016-17)  
Bishoy Saleeb, MPH, Drexel (2016-17)  
Scott Schneider, MPH, Drexel (2016-17)  
Kara Fisher, MPH Biostatistics, Drexel (2015-16)  
Matthew Hope, MPH, Drexel (2015-16)  
Adriane McKinney, MPH, Drexel (2015-16)  
Vanessa Moy, MPH, Drexel (2015-16)  
Daniel Shin, MPH, Drexel (2015-16)  
Keyuri Joshi, MPH, Drexel (2014-15)  
Zohra Roowala, MPH, Drexel (2014-15)

Nehchal Singh MPH, Drexel (2014-15)

**Predoctoral/Post-Baccalaureate Research Assistants [Placement]**

Amber Ni (2026-)

Toni Mankowitz\* (2024-)

Matthew Bonci\* (2019-20) [University of Chicago, MA Data Analytics and Research Methods]

**Student Research Assistants and Interns**

Natasha Antonich, BS Public Policy, USC (2025-26)

- Recipient, USC Price Student Undergraduate Research Experience (SURE) Scholarship

Matteus Schmidt, BS Economics and Mathematics, USC (2025)

Alyssa Tinoco, BA Political Science, USC (2024-25)

Rohan Bhatia, MS Data Science, USC (2024)

Jorge Gonzalez, BA Health and Human Sciences, USC (2024)

Anvi Surapaneni, BS Biochemistry, USC (2024)

Harrison Wang, MD candidate, USC (2023)

Toni Mankowitz\*, BS Public Policy, USC (2023)

- Recipient, USC Provost Undergraduate Research Fellowship

Elise Wimberly, BS Public Policy, USC (2023)

Leilei Hao, BA Computational Biology, Penn (2021-23)

Soham Mahadik, BSE Computer Science, Penn (2021-22)

Anchita Batra, BA Neuroscience and Economics, Penn (2021-22)

Neel Vallurupalli\*, BA Neuroscience, Penn (2020-21)

Faith Arimoro, MD, Penn (2020-21)

Alisa Bhakta, BSE Bioengineering, BS Finance, Penn (2018)

Olivia Darko, BA Health and Societies, Penn (2018)

Charles Gray, MS Economics, Drexel (2014-16)

Alec McQuilkin, MA/MS Economics/Mathematics, University of Colorado (2014-15)

Kelly Adams, JD, University of Colorado (2014-15)

Melanie Mason Whittington, PhD Health Services Research, University of Colorado (2014)

Rose Hardy, PhD Health Services Research, University of Colorado (2013-14)

Xin Zhao, PhD Economics, University of Colorado (2014)

John Sherman, JD, University of Colorado (2014)

Collin Whelley, MA Political Science, University of Colorado (2013-14)

Igor Gorlach\*, JD MPH, Harvard (2011-12)

Kenneth Oshita, AB Economics, University of Chicago (2012)

Grace Njau, MPH, University of Colorado (2011-12)

Megan Carlson, AB Political Science, University of Chicago (2008-09)

**Selected Research Seminar and Conference Presentations**

*Managing Conflicts of Interest and Industry Influence in Advisory Committees*

American Society of Health Economists Annual Meeting (ASHEcon) (2026)

Annual Health Economics Conference (AHEC) (2026)

ASSA/AEA Annual Meeting (2026)

APPAM Annual Meeting (2025)

*Financial Conflicts of Interest Among FDA Advisory Committee Members*

Yale Collaboration for Regulatory Rigor, Integrity, and Transparency (2023)

*Vertical Integration of Physician Practices and Pharmacies in Oncology*

AcademyHealth Research Meeting (2023)

*Coordination of Care or Conflicts of Interest?*

Harvard University Program on Regulation, Therapeutics, and Law (2022)

### **Invited Lectures, Panels, and Plenaries**

Jorge Llinares Memorial Lecture, European Medicines Agency (2026)

*Regulatory Capture and the Revolving Door in Drug Approvals*

Health Affairs Insider Event (2026)

*Panel: FDA and Its Changing Relationship to Industry*

FDA CERSI Innovations in Regulatory Science Summit (2024)

*Debate: FDA Advisory Committee Members Should Always Vote (No position)*

Doctors for America National Leadership Conference (2022)

*Panel: Too Many Cooks in the Kitchen: Consultants, Medical Societies, and Conflict of Interest in FDA Regulatory Review*

AAMC Forum on Conflict of Interest in Academe (2022)

*Plenary: 10 Years In: Reflections on How Disclosure Has Changed Since the PHS Revisions*

Precision Medicine Leaders Summit [virtual] (2020)

*Economic Issues in Precision Medicine*

### **Editorial Activities**

#### **Editorial Boards**

BMC Medical Ethics (Springer Nature Journals) (2022-)

BMC Health Services Research (Springer Nature Journals) (2021-22)

Harvard University Safra Center for Ethics Working Paper Series (2012-15)

#### **Reviewer Recognition**

JAMA Internal Medicine, Distinguished Reviewer (2026)

Health Affairs Scholar, Peer Review Board (2026)

JAMA Reviewer Recognition Award (2023, 2024)

Annals of Internal Medicine Reviewer Recognition Award (2023, 2024)  
Pharmacoepidemiology and Drug Safety, Reviewer Recognition Award (2021)

**Ad Hoc Peer Review**

*American Journal of Public Health*  
*Annals of Internal Medicine*  
*BMC Health Services Research*  
*BMJ Open*  
*BMJ*  
*CHEST*  
*Health Affairs*  
*Health Affairs Scholar*  
*Health Policy and Technology*  
*Health Services Research*  
*Healthcare Policy*  
*International Journal of Epidemiology*  
*JAMA*  
*JAMA Cardiology*  
*JAMA Health Forum*  
*JAMA Internal Medicine*  
*JAMA Network Open*  
*Journal of General Internal Medicine*  
*Journal of Health Politics, Policy, and Law*  
*Journal of Law, Medicine, and Ethics*  
*Medical Care Research and Review*  
*Milbank Quarterly*  
*New England Journal of Medicine*  
*Pediatrics*  
*Pharmacoepidemiology and Drug Safety*  
*PLoS Medicine*  
*Science*  
*Science and Engineering Ethics*

*American Journal of Health Economics*  
*Economic Journal*  
*Economics and Human Biology*  
*Journal of Human Resources*  
*Journal of Political Economy*  
*Journal of Policy Analysis and Management*  
  
*American Journal of Sociology*  
*BMC Geriatrics*  
*Organizational Behavior and Human Decision Processes*  
*Population Studies*  
*Social Science and Medicine*  
  
Cambridge University Press  
McGraw Hill  
Oxford University Press

**Grant Review Activities**

National Institute for Health Care Management (NIHCM) Foundation, Investigator-Initiated Research Grants (2023-26)  
Edmond J Safra Center for Ethics at Harvard University, Grants and Fellowships (2012)  
University of Colorado Clinical and Translational Sciences Institute, Pilot Grants (2011-14)

**Professional Activities**

Association for Public Policy Analysis & Management (APPAM) Fall Research Conference  
*Discussant* (2025)  
*Abstract Reviewer* (2025)

AcademyHealth Health Economics Interest Group Advisory Committee

*Chair* (2023-24)

*Vice Chair* (2022-23)

*Co-Chair, Mentoring Program Subcommittee* (2022-23; 2021-22)

*Scientific Program Reviewer* (2021-22)

*Member-at-Large* (2021-22)

Annual Health Economics Conference

*Discussant* (2023, 2024)

American Society of Health Economists

*Discussant* (2021, 2024)

*Scientific Program Reviewer* (2012-16)

University of Pennsylvania Institute for Translational Medicine and Therapeutics

*External Member, Ethics Working Group on Institutional Conflicts of Interest* (2022-24)

University of Chicago, Center on the Demography and Economics of Aging at NORC

*Member, External Advisory Board* (2016-18)

St Louis University, Bander Center for Medical Business Ethics

*Member, Expert Panel, Medical Business Ethics Curriculum Development* (2012-13)

### **Policy Engagement and Government Consultation**

Medicare Evidence Development and Coverage Advisory Committee (MEDCAC), Centers for Medicare and Medicaid Services (CMS)

*Member* (2022-present)

US Government Accountability Office (GAO)

*Research cited* in FDA Advisory Committees: More Transparency Needed on Policies for Making Conflict of Interest Determinations, Report No. GAO-26-107877 (Mar 24, 2026) [\[link\]](#)

US Senate Finance Committee

*Research cited* in Setting the Record Straight: An Accounting of Secretary Robert F Kennedy, Jr's September 5, 2025 Testimony on the CDC & Vaccines. Senate Finance Committee Minority Staff Report (September 16, 2025) [\[link\]](#)

US Senate Finance Committee.

*Research cited* during congressional hearing: Hearing on the President's 2026 Health Care Agenda (September 4, 2026) [\[link\]](#)

US Government Accountability Office (GAO)

*Consulted by GAO staff* on FDA advisory committee conflict-of-interest research (2025)

US Senate, Office of Senator Elizabeth Warren  
*Advised congressional staff* on CDC conflict of interest policy (2025)

US Department of Health and Human Services  
*Research cited* in proposed rule. HIPAA Security Rule to Strengthen the Cybersecurity of Electronic Protected Health Information (January 6, 2025) [\[link\]](#)

US Food and Drug Administration  
*Public comment* on Optimizing the Food and Drug Administration's Use of and Processes for Advisory Committees, Docket No. FDA-2024-N-1809 (August 13, 2024) [\[docket link\]](#) [\[comment link\]](#)

**University, School, and Departmental Service**

Bedrosian Chair Search Committee, USC Price  
*Member* (2025-26; 2026-27)

Faculty Council, USC Price  
*Member at-large* (2025-26; 2026-27)  
*Vice Chair* (2025)

Bachelor of Public Policy (BSPP) Committee, USC Price  
*Member* (2025-26; 2026-27)

Seminar Committee, USC Schaeffer Center for Health Policy and Economics  
*Member* (2024-25; 2025-26; 2026-27)

Admitted Students' Day, USC Price  
*Faculty Panelist* (2024-25; 2025-26)

Curriculum Committee, USC Price, Department of Health Policy and Management  
*Member* (2023-24; 2024-25; 2025-26)

Faculty Search Committee, Penn Medicine, Department of Medical Ethics and Health Policy  
*Member* (2021-22)

Doctoral Program Oversight Committee, Drexel School of Public Health, Department of Health Management and Policy  
*Member* (2015-17)

School-wide Doctoral Committee, Drexel School of Public Health  
*Member* (2015-17)

Jonathan Mann Memorial Lecture Speaker Selection Committee, Drexel School of Public Health

*Member (2014-17)*

Junior Faculty Search Committee, Drexel School of Public Health, Department of Health Management and Policy

*Member (2015-16)*

Joint Public Health-Business School Committee, Drexel School of Public Health, Department of Health Management and Policy

*Member (2015)*

PhD Health Services Research Admissions Committee, Colorado School of Public Health

*Member (2013-14)*

PhD Health Economics Program Development Committee, Colorado School of Public Health

*Member (2012-14)*

### **External Outreach**

Association of Health Care Journalists Annual Meeting (2025)

Panel: *Finding True Efficiencies in Health Care*

National Association of Science Writers and the Council for the Advancement of Science Writing Annual Joint Meeting (2019)

Panel: *Full Disclosure: Reporting on Scientists' Conflicts of Interest*

### **Interviews and Media Mentions**

*National and General News:* New York Times, Washington Post, Wall Street Journal, Reuters, AP, CNN, NBC, NPR, Newsmax, Atlantic, Daily Beast, Wired, FiveThirtyEight, Observer, Philadelphia Inquirer, Chicago Tribune, Houston Chronicle, Cincinnati Enquirer, GBH (Boston Public Radio) Curiosity Desk

*Policy and Business:* Politico, The Hill, Axios, Bloomberg, Forbes, Fortune, CNBC, Bloomberg Law, The Intercept

*Science and Health:* STAT News, KFF Health News, The Examination, Science, Nature, BMJ News, MedPage Today, Medscape, Fierce Healthcare, Fierce Pharma, Modern Healthcare, Becker's Hospital Review, BioSpace, BioPharma Dive, Regulatory Focus, PharmaVoice

*Podcasts:* Deep Background with Noah Feldman, Calling Bullsh!t

Detailed list of interviews and media mentions available at: <https://kanterresearch.org/media>

**Grants and Contracts**

**Ongoing Support**

**Centers for Medicare and Medicaid Services (Contract PI: Goldman, Liu)**

*Economic and Policy Analyses to Inform CMS Priorities* 9/3/26-1/28/27

The purpose of this project is to quantify potential savings from identifying and preventing fraud and waste in Medicare and Medicaid.

Role: Project Lead

**Arnold Ventures (PI: Kanter)**

4/9/26-10/31/27

*Advisory Committee Accountability Project (ACAP): Research and Policy Hub*

The purpose of the Advisory Committee Accountability Project Research and Policy Hub is to conduct research that drives evidence-based policies that strengthen the integrity of federal advisory committees.

Role: Principal Investigator

**Arnold Ventures (PI: Duquette)**

1/1/26-12/31/27

*The Administration and Tax Policy of Charitable Giving*

The purpose of this research is to examine the effects of changes in the corporate tax code on patterns of corporate charitable giving overall and specifically in the health and finance sectors.

Role: Co-Investigator

**Completed Research Support**

**Arnold Ventures (PI: Kanter)**

7/1/23-6/30/26

*Conflicts of Interest Among Consumer and Patient Representatives on FDA Advisory Committees*

The purpose of this research is to examine the effects of financial conflicts of interest among consumer and patient representatives serving on FDA advisory committees.

Role: Principal Investigator

**P30 AG043073-12S1 (PI: Zissimopoulos; Supplement PI: Kanter)**

9/1/24-6/30/26

**NIH/NIA**

*Disparities in Access to Critical Imaging Technologies for ADRD Diagnosis and Treatment*

The purpose of this research is to analyze disparities in access to critical imaging technologies used in the diagnosis and treatment of Alzheimer's disease and related diseases.

Role: Principal Investigator for Supplement

**I01 HX003345 (PI: Groeneveld)**

**VA HSR&D**

6/1/22-5/31/25

*Impact of the MISSION Act on Quality and Outcomes of Interventional Cardiology and Cardiac Surgery Among Veterans*

The purpose of this research is to evaluate the effect of a program that finances care received outside of VHA facilities on interventional cardiology and cardiac surgery quality and outcomes.

Role: Co-Investigator

**Arnold Ventures (PI: Kanter)**

4/12/24-3/11/25

*ISPOR 2024 – Educational Symposium on FDA Advisory Committees*

The purpose of this grant is to convene national leaders at the annual ISPOR conference to discuss the role of expert advice in government decision-making and how to improve the functioning of FDA advisory committees.

Role: Principal Investigator

**National Institute for Health Care Management Foundation (PI: Kanter)** 1/1/21-10/31/23

*Medically Integrated Dispensing in Oncology*

The purpose of this project is to examine trends in medically integrated dispensing (physician-pharmacy integration) among community oncology practices.

Role: Principal Investigator

**Robert Wood Johnson Foundation (PI: Lau-Min)**

12/1/21-11/30/22

*Evaluating the Impact of Targeted Cancer Drug Value on Utilization and Patient Out-of-Pocket Spending*

The purpose of this research is to compare the uptake of high-, medium-, and low-value targeted cancer drugs over time and determine the impact of drug value on out-of-pocket spending.

Role: Co-Investigator

**R01 MD015055 (PI: Navathe)**

9/23/21-12/31/22

**NIH/NIMHD**

*The Impact of Population and Episode-Based Payment Models on Surgical Disparities*

The purpose of this research is to examine how population- and episode-based alternative payment models affect equity in access to and outcomes for a range of surgical procedures.

Role: Co-Investigator

**R33 AG057380 (PI: Patel)**

3/1/21-8/31/21

**NIH/NIA**

*Leveraging the Electronic Health Record to Nudge Clinicians to Prescribe Evidence-Based Statin Medications to Reduce the Risk of Cardiovascular Disease*

The purpose of this research is to evaluate the effect of EHR-integrated nudges on evidence-based prescribing of statins.

Role: Co-Investigator

**R01 HS025184 (PI: Werner)**

7/1/17-3/31/21

**AHRQ**

*The Impact of ACOs on Disparities*

The purpose of this research is to examine the effect of accountable care organizations on disparities in patient outcomes.

Role: Co-Investigator

**Commonwealth of Kentucky (PI: Volpp)**

10/1/18-4/13/20

*Evaluation of the Health and Economic Consequences of Kentucky's Section 1115 Demonstration Waiver*

The purpose of this research is to evaluate the health and economic impact of the Commonwealth of Kentucky's modified Medicaid program, focusing on its substance use disorder interventions, community engagement requirements, and incentivized savings accounts.

Role: Co-Investigator

**R01 HS023615 (PI: Groeneveld)**

7/1/18-9/29/19

**AHRQ**

*Market and Organization Impact on Medical Technology Diffusion: Outcomes and Value*

The purpose of this research is to study the effect of changes in health care markets and the organization of the health care system on the adoption of new medical technologies.

Role: Co-Investigator

**Laura and John Arnold Foundation (PI: Anderson)**

11/1/16-10/31/17

*Policy Options to Reduce Prescription Drug Spending*

The purpose of this research is to evaluate policy options related to prescription drug prices and spending.

Role: Consultant

**Greenwall Foundation (PI: Kanter)**

8/1/14-7/31/15

*Consumer Responses to Disclosure of Physician Payments*

The purpose of this research is to examine consumer responses to the nationwide public disclosure of industry payments information.

Role: Principal Investigator

**Edmond J. Safra Philanthropic Foundation (PI: Kanter)**

9/1/13-7/31/15

*Theoretical and Empirical Issues in Conflicts of Interest in Medicine*

The purpose of this research is to synthesize conceptual issues and empirical findings related to conflicts of interest in medicine.

Role: Principal Investigator

**R01 HG006281 (PI: Campbell)**

11/1/11-6/31/14

**NIH/NHGRI**

*Data Sharing and Data Withholding in Genetics*

The purpose of this research is to study recent historical trends in and factors related to data sharing and data withholding in genetics and the life sciences.

Role: Co-Investigator

**Edmond J. Safra Philanthropic Foundation (PI: Kanter)**

9/1/11-7/31/13

*Conflicts of Interest at the FDA*

The purpose of this research is to examine the effects of financial conflicts of interest on the behavior of FDA advisory committee members.

Role: Principal Investigator